The Chaperone Arrives: Protego Bets on a Star CMO to Conquer a Rare Disease

SAN DIEGO, CA – June 08, 2026

In the high-stakes world of biotechnology, executive appointments are rarely just about filling a chair. They are signals of intent, strategic chess moves that can telegraph a company’s entire game plan. Today, Protego Biopharma, a clinical-stage company with ambitious goals, made its move crystal clear with the appointment of Jae B. Kim, MD, as its new Chief Medical Officer.

For a company on the cusp of advancing its lead drug into pivotal trials, bringing in a figure like Dr. Kim is akin to hiring a seasoned alpinist to guide a well-funded expedition to the summit. Dr. Kim is not just an experienced executive; he is a veritable architect of drug approvals, with a resume studded with some of the most significant therapies for cardiovascular and rare diseases developed in the last decade. His arrival at Protego is a powerful statement that the company is not just hoping for success—it is meticulously engineering it.

A Strategic Play for a Pivotal Moment

Protego Biopharma is at a critical juncture. The San Diego-based firm recently closed an oversubscribed $130 million Series B financing round in December 2025, bringing its total capital raised to an impressive $181 million. This infusion of cash was explicitly earmarked to push its lead candidate, PROT-001, into late-stage clinical trials for light chain (AL) amyloidosis, a rare and often fatal disease.

With the financial fuel secured, the next logical step was to acquire the human capital to navigate the complex, multi-year journey of global drug registration. In hiring Dr. Kim, Protego has found a leader whose experience directly maps onto its needs. As Brent J. Warner, CEO of Protego, noted, "Dr. Kim is an accomplished healthcare executive who brings to Protego a wealth of experience in advancing novel therapies." He added that Dr. Kim joins "at an opportune time to help advance our lead program... into pivotal studies this year."

This is more than just opportune timing; it’s a calculated investment. The biotech industry is littered with promising science that faltered in the treacherous terrain of Phase 3 trials and regulatory review. By bringing in a CMO who has successfully navigated this path multiple times, Protego is de-risking its most valuable asset and signaling to investors and the wider medical community that it is executing a deliberate, expert-led strategy.

The Human Cost of Misfolding Proteins

To understand the significance of this move, one must understand the disease Protego aims to conquer. Light chain amyloidosis is a cruel and insidious condition. It begins when antibody-producing plasma cells in the bone marrow malfunction, producing abnormal protein fragments—light chains—that misfold. Instead of being cleared by the body, these misshapen proteins clump together to form amyloid fibrils, which then accumulate in vital organs like the heart, kidneys, and liver, causing progressive and catastrophic damage.

For patients, a diagnosis can be a death sentence. The disease often leads to severe cardiomyopathy or renal failure. While current treatments, which often involve chemotherapy or stem cell transplants, have improved, they primarily focus on destroying the plasma cells that produce the rogue proteins. They are grueling and do not address the underlying protein instability.

This is where Protego’s science offers a paradigm shift. PROT-001 is not designed to kill cells or clear existing amyloid plaques. It is a small-molecule drug known as a “pharmacological chaperone.” In simple terms, it is designed to bind to the unstable light chains and stabilize them, preventing them from misfolding and aggregating in the first place. It is a therapy aimed at the root cause, a preventative measure at the molecular level. As Dr. Kim stated, his goal is to "potentially change the standard of care by addressing the root cause of this disease."

The Architect of Approvals

If PROT-001 is the innovative tool, Dr. Jae B. Kim is the master craftsman hired to wield it. His track record is a testament to his ability to shepherd complex therapies from the lab to the pharmacy shelf. Before joining Protego, he held CMO roles at Septerna and Design Therapeutics, but it is his previous work that truly illuminates his value.

During his time at Alnylam Pharmaceuticals, MyoKardia, and Amgen, Dr. Kim was instrumental in the development and approval of a slate of transformative drugs. The list includes Givlaari and Amvuttra, both for rare diseases; Leqvio and Repatha, for cholesterol management; and Camzyos, a groundbreaking treatment for a form of cardiomyopathy. The latter is particularly relevant, given that AL amyloidosis frequently attacks the heart, and Dr. Kim himself is a board-certified cardiologist with a faculty history at Harvard Medical School. His deep expertise in both rare disease and cardiovascular medicine makes him uniquely qualified to oversee the development of PROT-001.

This history is not just a list of accomplishments; it's a pattern of success in the very areas where Protego operates. Dr. Kim has repeatedly demonstrated a knack for guiding novel mechanisms of action through regulatory scrutiny, a skill that will be invaluable as Protego prepares to make its case to the FDA and other global health authorities. His stated "passion for addressing rare diseases with serious unmet medical needs" is not just a sentiment; it is the common thread running through his entire career.

From Bench to Bedside: The Path Forward

The immediate task for Dr. Kim is to lead PROT-001 into “pivotal studies.” These are the large-scale, definitive Phase 3 trials required to prove a drug's safety and efficacy to regulators. The company’s stated ambition to pursue “accelerated and full approval” signals its confidence. The FDA’s accelerated approval pathway is reserved for drugs that treat serious conditions and provide a meaningful advantage over available therapies, allowing them to reach patients sooner while post-marketing studies continue.

Protego’s scientific lineage adds another layer of credibility to this ambition. The company’s co-founders were instrumental in the discovery and development of tafamidis (marketed as Vyndaqel), a successful therapy for a different type of amyloidosis. This history demonstrates a deep, institutional knowledge of the protein misfolding field.

With a well-capitalized balance sheet, a novel scientific approach, a clear line of sight to pivotal trials, and now a celebrated drug developer at the clinical helm, Protego Biopharma has assembled all the necessary components for a breakthrough. For the thousands of patients suffering from light chain amyloidosis, this carefully orchestrated strategy represents a tangible new form of hope. The entire industry will be watching to see if this combination of innovative science and veteran leadership can successfully chaperone a new standard of care into existence.